"10.1371_journal.pone.0026885","plos one","2011-10-28T00:00:00Z","Allison Martin; Janaki Amin; Sean Emery; David Baker; Andrew Carr; David A Cooper; Mark Bloch","The Kirby Institute (formerly the National Centre in HIV Epidemiology and Clinical Research), University of New South Wales, Sydney, New South Wales, Australia; East Sydney Doctors, Sydney, New South Wales, Australia; St Vincent's Hospital and St Vincent's Centre for Applied Medical Research, Sydney, New South Wales, Australia; Holdsworth House Medical Practice, Sydney, New South Wales, Australia","Conceived and designed the experiments: AM JA SE DB AC DAC MB. Performed the experiments: AM JA MB. Analyzed the data: AM JA. Wrote the paper: AM JA MB.","Allison Martin has received some research funding from Gilead Sciences. Janaki Amin declares no conflict of interest. David Cooper received research funding from Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen-Cilag, Merck, and Pfizer; consultancy fees, lecture and travel sponsorships from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck, and Pfizer; and has served on advisory boards for Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Merck, and Pfizer. Andrew Carr has received research funding from Abbott, Merck and Roche; consultancy fees from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck and Roche; lecture sponsorships from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck and Roche; and has served on advisory boards for Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck and Roche. Andrew Carr is also on the editorial board of PLoS Medicine. Mark Bloch has received research funding from GlaxoSmithKline, Gilead, Abbott, Merck, Pfizer, Boehringer-Ingelheim and Novartis and travel sponsorships from GlaxoSmithKline, Abbott, Merck, Pfizer and Novartis, and has served on advisory boards for GlaxoSmithKline, Boehringer-Ingelheim, Pfizer, Merck and Janssen-Cilag. David Baker has received research funding from Bristol-Myers Squibb and Merck, consultancy fees from Bristol-Myers Squibb, lecture and travel sponsorships from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline and Tibotec, and has served on advisory boards for Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead and Tibotec. Sean Emery has either served on advisory boards; received travel grants, consultancy payments or honoraria from Bristol-Myers Squibb, Gilead, Janssen-Cilag, NeuroMolecular Pharmaceuticals, RDI, Roche and Virax. Sean is also an academic editor for PLoS ONE. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","10","Allison Martin","AM",7,TRUE,7,3,2,3,TRUE,TRUE,FALSE,0,NA,FALSE
